Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win

AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win

  • April 20, 2026

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win, offering further evidence the Big Pharma may have cracked the anti-IL-33 code.

Leave A Comment

Fields (*) Mark are Required